Maxygen, Inc. (NASDAQ:MAXY)

CAPS Rating: 4 out of 5

A biotechnology company committed to the discovery and development of improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions.

Recs

0
Player Avatar HunNemo (66.65) Submitted: 7/21/2010 9:36:28 AM : Outperform Start Price: $4.76 MAXY Score: +1.02

cheap biotech

Featured Broker Partners


Advertisement